Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 13/20 | 0.49 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.49 |
| ▸ | GPR174 | Q9BXC1 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28350789 | 0.83 | P2RY10 (0.55) | P2RY10GPR34GPR174 | |
| SCHEMBL1254622 | 0.82 | P2RY10 (0.47) | P2RY10GPR34GPR174 | |
| SCHEMBL21067424 | 0.81 | P2RY10 (0.47) | P2RY10GPR34GPR174 | |
| SCHEMBL13618513 | 0.81 | P2RY10 (0.60) | P2RY10GPR34GPR174 | |
| SCHEMBL19347656 | 0.81 | P2RY10 (0.50) | P2RY10GPR34GPR174 | |
| SCHEMBL17927564 | 0.81 | P2RY10 (0.46) | P2RY10GPR34GPR174 | |
| SCHEMBL18501623 | 0.81 | P2RY10 (0.40) | P2RY10GPR34GPR174 | |
| SCHEMBL26229066 | 0.81 | P2RY10 (0.40) | P2RY10GPR34GPR174 | |
| SCHEMBL22567208 | 0.80 | S1PR1 (0.43) | P2RY10GPR34GPR174 | |
| SCHEMBL12609430 | 0.80 | P2RY10 (0.44) | P2RY10GPR34GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136339-B2 | Dihydroartemisinin diploid derivative, pharmaceutical composition thereof, and application | SOUTHEAST UNIVERSITY (CN) | 2021-10-05 | — | — | US | disclosed |
| US-20200040008-A1 | DIHYDROARTEMISININ DIPLOID DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SOUTHEAST UNIVERSITY (CN) | 2020-02-06 | — | — | US | disclosed |
| US-8822670-B2 | Method of synthesizing cDNA and method of synthesizing RNA chains, and nucleotide-immobilized carrier | SUMITOMO BAKELITE COMPANY, LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8198020-B2 | Contacting target cell or noncellular molecular entity with phagocytic marker and moiety that binds to a component that is present on or at surface of target cell or noncellular molecular entity, thereby increasing level or density of phagocytic marker on target cell; marker comprises phosphatidylserine | POTENTIA PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100016566-A1 | Method of synthesizing cdna and method of synthesizing rna chains, and nucleotide-immobilized carrier | KINOSHITA, KENJI (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016566-A1 | Method of synthesizing cdna and method of synthesizing rna chains, and nucleotide-immobilized carrier | RNGTT, POLRMT, RNMT | P2RY10 3742/4885GPR34 3449/4885GPR174 2639/4885 |
| US-20200040008-A1 | DIHYDROARTEMISININ DIPLOID DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SSB, DHODH, QTRT1 | P2RY10 1080/4885GPR34 3742/4885GPR174 3911/4885 |
| US-11136339-B2 | Dihydroartemisinin diploid derivative, pharmaceutical composition thereof, and application | SSB, DHODH, QTRT1 | P2RY10 1080/4885GPR34 3742/4885GPR174 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.